Neoadjuvant Chemotherapy in Advanced Penile Carcinoma

Leijte, Joost A.P.; Kerst, J. Martijn; Bais, Evert; Antonini, Ninja; Horenblas, Simon

doi:10.1016/j.eururo.2007.02.006

Cited by 159 publications

(68 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…5,57 Recent data, however, suggest that response to salvage treatment in patients previously treated with TIP was low (Box 10).…”

Section: Chemotherapy For Locally Recurrent Diseasementioning

confidence: 99%

“…In a retrospective analysis, 12 out of 19 patients receiving neoadjuvant chemotherapy with different regimens (vincristine/ bleomycin/methotrexate, cisplatinum/bleomycin/methotrexate, cisplatinum/5-FU or cisplatinum/irinotecan) responded, and 8 of these patients achieved long-term survival after subsequent resection of the inguinal lymph node metastases. 57 Bermejo and colleagues reported a complete response in 4 out of 5 patients receiving neoadjuvant treatment with paclitaxel/cisplatinum/ifosfamide, 3 of whom had a histologically demonstrated complete response. 82 Cisplatinbased combinations showed similar benefit to bleomycin containing regimen in penile cancer, while avoiding the observed significant bleomycin-related toxicity.…”

Section: Neoadjuvant Chemotherapymentioning

confidence: 99%

“…Leijte and colleagues evaluated 5 separate regimens, including bleomycin-methotrexate-cisplatin (BMP) and cisplatin-5-FU (adopted from squamous cell carcinomas of the head and neck). 57 Response rates were 33% to 63%; however, bleomycin-containing regimens were associated with increased toxicity and a high rate of treatment-related deaths. Importantly, the authors found that patients achieving objective response to chemotherapy benefitted the most from surgery with a chance for cure.…”

Section: Unresectable and Metastatic Diseasementioning

confidence: 99%

See 2 more Smart Citations

Management of carcinoma of the penis: Consensus statement from the Canadian Association of Genitourinary Medical Oncologists (CAGMO)

Richter

Ruether

Wood

et al. 2013

CUAJ

View full text Add to dashboard Cite

“…5,57 Recent data, however, suggest that response to salvage treatment in patients previously treated with TIP was low (Box 10).…”

Section: Chemotherapy For Locally Recurrent Diseasementioning

confidence: 99%

Section: Neoadjuvant Chemotherapymentioning

confidence: 99%

Section: Unresectable and Metastatic Diseasementioning

confidence: 99%

See 1 more Smart Citation

Management of carcinoma of the penis: Consensus statement from the Canadian Association of Genitourinary Medical Oncologists (CAGMO)

Richter

Ruether

Wood

et al. 2013

CUAJ

View full text Add to dashboard Cite

“…In a retrospective analysis, 12 out of 19 patients receiving neoadjuvant chemotherapy with different regimens (vincristine/bleomycin/ methotrexate, cisplatinum/bleomycin/methotrexate, cisplatinum/5-FU or cisplatinum/irinotecan) were reported to show a response and eight of these patients achieved long-term survival after subsequent resection of the inguinal lymph node metastases [Leijte et al 2007 ]. Bermejo and colleagues reported a complete response in four out of five patients receiving neoadjuvant treatment with paclitaxel/cisplatinum/ifosfamide, three of whom had a histologically proven complete response [Bermejo et al 2007].…”

Section: Neoadjuvant Chemotherapymentioning

confidence: 99%

Chemotherapy in Penile Cancer

Protzel¹,

Hakenberg²

2014

Management of Penile Cancer

View full text Add to dashboard Cite

Abstract:Penile cancer is an aggressive disease and after systemic progression it is virtually incurable. While this squamous cell cancer responds to chemotherapy, successful treatment of lymphatic metastases can only be achieved with aggressive surgical treatment in combination with chemotherapy. However, because penile carcinoma is relatively rare there is a paucity of clinical data on the chemotherapy for this aggressive disease. Recent advances have included the establishment of less toxic regimens incorporating taxanes, while cisplatinum remains central to all regimens. Multi-institutional studies are urgently needed to advance the multimodal care for patients with penile cancer.

show abstract

“…20,21 Numerous regimens with variable cycles were employed in these retrospective studies, most commonly ifosfamide, paclitaxel and cisplatin, and bleomycin, methotrexate and cisplatin. Response rates were 50% and 63% in these series, with 5-year survival in responders at 40% and 56%.…”

Section: Chemotherapy In Penile Cancermentioning

confidence: 99%

What next? Managing lymph nodes in men with penile cancer

Leveridge

Morash

2013

CUAJ

View full text Add to dashboard Cite

The management of patients with squamous cell carcinoma of the penis is often daunting given its rarity and subsequent lack of high-level evidence to support our decision-making. This culminates in the complex surgical issues involving the management of the regional lymph nodes, which is of critical importance to both quantity and quality of life for these patients. This review aims to highlight the decisive issues surrounding the management of the pelvic and inguinal lymph nodes in the setting of squamous cell carcinoma of the penis, and to spotlight recently published information that adds credence to accepted management strategies of both the clinically positive and negative groin after successful management of the primary lesion.

show abstract

Neoadjuvant Chemotherapy in Advanced Penile Carcinoma

Cited by 159 publications

References 22 publications

Management of carcinoma of the penis: Consensus statement from the Canadian Association of Genitourinary Medical Oncologists (CAGMO)

Management of carcinoma of the penis: Consensus statement from the Canadian Association of Genitourinary Medical Oncologists (CAGMO)

Chemotherapy in Penile Cancer

What next? Managing lymph nodes in men with penile cancer

Contact Info

Product

Resources

About